• 1
    Inuyama Symposium Kiroku Kanko-kai. Hepatitis Type A and Fulminant Hepatitis. The Proceedings of the 12th Inuyama Symposium. Tokyo: Chugai Igaku-sha, 1982. (In Japanese.)
  • 2
    Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. The Study Group of Fulminant Hepatitis. J Gastroenterol Hepatol 1991; 6: 159164.
  • 3
    Gimson AE, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288294.
  • 4
    Mochida S, Takikawa Y, Nakayama N et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011; 41: 805812.
  • 5
    Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol 2012; 47: 849861.
  • 6
    Sato S, Suzuki K, Takikawa Y, Endo R, Omata M, Japanese National Study Group of Fulminant H. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res 2004; 30: 155161.
  • 7
    Fujiwara K, Mochida S, Matsui A et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 2008; 38: 646657.
  • 8
    Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012; 42: 627636.
  • 9
    Mochida S, Fujiwara K. Symposium on clinical aspects in hepatitis virus infection. 2. Recent advances in acute and fulminant hepatitis in Japan. Intern Med 2001; 40: 175177.
  • 10
    Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 16441655.
  • 11
    Mori M, Itanai F, Washio S. Estimated number of patients with intractable liver diseases in Japan based on nationwide epidemiology surveillance. Annual Report of Epidemiology Research for Intractable Diseases in Japan, the Ministry of Health, Welfare and Labor (2005). 2006: 3942. (In Japanese.)
  • 12
    Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 20032009.
  • 13
    Dhiman RK, Jain S, Maheshwari U et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 2007; 13: 814821.
  • 14
    Schiodt FV, Chung RT, Schilsky ML et al. Outcome of acute liver failure in the elderly. Liver Transpl 2009; 15: 14811487.
  • 15
    Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605611.
  • 16
    Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 5968.
  • 17
    Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003; 362: 371373.
  • 18
    Inoue J, Ueno Y, Nagasaki F et al. Sporadic acute hepatitis E occurred constantly during the last decade in northeast Japan. J Gastroenterol 2009; 44: 329337.
  • 19
    Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011; 46: 378390.
  • 20
    Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute-onset autoimmune hepatitis. Hepatology 2011; 54: 371372.
  • 21
    Stravitz RT, Lefkowitch JH, Fontana RJ et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011; 53: 517526.
  • 22
    Inoue K, Kourin A, Watanabe T, Yamada M, Yoshiba M. Artificial liver support system using large buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplant Proc 2009; 41: 259261.
  • 23
    Yokoi T, Oda S, Shiga H et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus Apher Sci 2009; 40: 6170.
  • 24
    Shinozaki K, Oda S, Abe R, Tateishi Y, Yokoi T, Hirasawa H. Blood purification in fulminant hepatic failure. Contrib Nephrol 2010; 166: 6472.
  • 25
    Arata S, Tanaka K, Takayama K et al. Treatment of hepatic encephalopathy by on-line hemodiafiltration: a case series study. BMC Emerg Med 2010; 10: 10.
  • 26
    Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 16561665.
  • 27
    Torii N, Hasegawa K, Ogawa M, Hashimo E, Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002; 24: 34.
  • 28
    Jochum C, Gieseler RK, Gawlista I et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009; 80: 235240.
  • 29
    Tsubouchi H, Kumada H, Kiyosawa K. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Acta Hepatol Jpn 2009; 50: 3842. (In Japanese.)
  • 30
    Yamashiki N, Sugawara Y, Tamura S et al. Outcome after living donor liver transplantation for acute liver failure in Japan; results of a nationwide survey. Liver Transpl 2012; 18: 10691077.
  • 31
    Sugihara J, Naito T, Ishiki Y et al. A multicenter study on the prognosis and indication of liver transplantation for fulminant hepatitis in Japan: details of decision of the guideline for liver transplantation in Japanese Acute Hepatic Failure Study Group. Acta Hepatol Jpn 2001; 42: 543557. (In Japanese.)
  • 32
    Mochida S, Nakayama N, Matsui A, Nagoshi S, Fujiwara K. Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res 2008; 38: 970979.
  • 33
    Naiki T, Nakayama N, Mochida S et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: application to indication criteria for liver transplantation. Hepatol Res 2012; 42: 6875.
  • 34
    Nakayama N, Oketani M, Kawamura Y et al. Novel classification of acute liver failure through clustering using a self-organizing map: usefulness for prediction of the outcome. J Gastroenterol 2011; 46: 11271135.
  • 35
    Nakayama N, Oketani M, Kawamura Y et al. Algorithm to determine the outcome of patients with acute liver failure: a data-mining analysis using decision trees. J Gastroenterol 2012; 47: 664677.